Computational chemistry and machine learning tools to accelerate drug discovery programs.
About
Founded
2017
Headquarters
Cambridge, Massachusetts
Industry
Biotech
Company Description
Reverie Labs is a pharmaceutical company that uses its innovative computational chemistry and machine learning tools to accelerate its drug discovery programs. Reverie's primary goal is to develop kinase inhibitors that address the unmet needs of patients.
First Round Capital, Ridgeback Capital Investments, Neo, Y Combinator
Company Traction
As of May 2023, Reverie Labs has four candidates in its pipeline: RVL-101 at IND-Enabling, RVL-102 at late discovery, RVL-103 at early discovery, and Multiple Roche / GNE at an undisclosed stage.
Leadership Team
Jonah Kallenbach: Co-Founder & CEO of Reverie Labs. Former Software Engineer Intern at Google.
Ankit Gupta: Co-Founder & CTO of Reverie Labs. Former Research Engineer at Vicarious AI.
John Campbell: VP of Chemistry at Reverie Labs. Former Director of Medical Chemistry at Blueprint Medicines.
Nisha Perez: VP of Preclinical Development & Clinical Pharmacology at Reverie Labs. Former Senior Director, Head of DMPK at ROME Therapeutics.
Bo-Sheng Pan: Head of Biology at Reverie Labs. Former Director, Pharmacology at Merck.
